{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T10:54:39Z","timestamp":1715943279945},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"Supplement_B","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Clostridioides difficile is a Gram-positive, anaerobic, spore-forming bacillus. It is isolated in 80% of the stools of children and infants and in 3% of healthy adults. It causes gastrointestinal tract infections and affects patients who make prolonged use of antibiotics. It causes C. difficile colitis with symptoms ranging from diarrhoea to pseudomembranous colitis to toxic megacolon. The main virulence factors of C. difficile are toxin A, toxin B, and binary toxin. It is one of the most common nosocomial infections but in recent years, however, many infections have also been found at the community level. They are associated not only with a high risk of mortality but also with a prolongation of hospital stay. One of the critical aspects of C. difficile infections is also represented by the high frequency of relapses. Consequently, the economic impact is significant. Specific situations constitute risk factors for infection, such as exposure to antibiotic therapy in the previous months, in particular fluoroquinolones, third-generation cephalosporins, clindamycin, repeated hospitalizations in healthcare facilities, including long-term care, as well as the patient\u2019s clinical conditions such as comorbidities, age &amp;gt;65, chemotherapy and immunosuppressive treatments, recent surgery of any type, and pump inhibitor therapy. Treatment protocols will be described in the paper.<\/jats:p>","DOI":"10.1093\/eurheartjsupp\/suad096","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T17:57:01Z","timestamp":1682099821000},"page":"B161-B165","source":"Crossref","is-referenced-by-count":1,"title":["Nightmare in the ward: difficult <i>Clostridioides<\/i> infection"],"prefix":"10.1093","volume":"25","author":[{"given":"Agapito","family":"Tarasi","sequence":"first","affiliation":[{"name":"UOC Internal Medicine, UOS Clinical Immunology, San Giovanni-Addolorata Hospital , Rome , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"2023042117450286000_suad096-B1","doi-asserted-by":"crossref","first-page":"010407","DOI":"10.7189\/jogh.09.010407","article-title":"Global burden of Clostridium difficile infections: a systematic review and meta-analysis","volume":"9","author":"Balsells","year":"2019","journal-title":"J Glob Health"},{"key":"2023042117450286000_suad096-B2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1056\/NEJMcp011603","article-title":"Clinical practice. Antibiotic-associated diarrhea","volume":"346","author":"Bartlett","year":"2002","journal-title":"N Engl J Med"},{"key":"2023042117450286000_suad096-B3","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1093\/cid\/cis335","article-title":"Burden of Clostridium difficile on the healthcare system","volume":"55","author":"Dubberke","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2023042117450286000_suad096-B4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1086\/659156","article-title":"Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals","volume":"32","author":"Miller","year":"2011","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2023042117450286000_suad096-B5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0140-6736(10)61266-4","article-title":"Clostridium difficile infection in Europe: a hospital-based survey","volume":"377","author":"Bauer","year":"2011","journal-title":"Lancet"},{"key":"2023042117450286000_suad096-B6","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1136\/pgmj.63.745.993","article-title":"Clostridium difficile colitis following treatment with metronidazole and vancomycin","volume":"63","author":"Bingley","year":"1987","journal-title":"Postgrad Med J"},{"key":"2023042117450286000_suad096-B7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2047-2994-2-21","article-title":"Epidemiology of Clostridium difficile infection in Asia","volume":"2","author":"Collins","year":"2013","journal-title":"Antimicrob Resist Infect Control"},{"key":"2023042117450286000_suad096-B8","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/cid\/cis614","article-title":"Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England","volume":"55","author":"Wilcox","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2023042117450286000_suad096-B9","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1086\/342691","article-title":"Clostridium difficile-associated diarrhea: epidemiological data from Western Australia associated with a modified antibiotic policy","volume":"35","author":"Thomas","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2023042117450286000_suad096-B10","doi-asserted-by":"crossref","first-page":"706","DOI":"10.5694\/j.1326-5377.2009.tb02644.x","article-title":"First Australian isolation of epidemic Clostridium difficile PCR ribotype 027","volume":"190","author":"Riley","year":"2009","journal-title":"Med J Aust"},{"key":"2023042117450286000_suad096-B11","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/archpediatrics.2010.282","article-title":"Clostridium difficile infection in hospitalized children in the United States","volume":"165","author":"Nylund","year":"2011","journal-title":"Arch Pediatr Adolesc Med"},{"key":"2023042117450286000_suad096-B12","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1093\/cid\/ciab549","article-title":"Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults","volume":"73","author":"Jonson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023042117450286000_suad096-B13","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1001\/jamainternmed.2016.6193","article-title":"Receipt of antibiotics in hospitalized patients and risk for Clostridium difficile infection in subsequent patients who occupy the same bed","volume":"176","author":"Freedberg","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2023042117450286000_suad096-B14","article-title":"FDA Drug Safety Communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs).","author":"US Food and Drug Administration"},{"key":"2023042117450286000_suad096-B15","article-title":"Antidepressants linked to doubling of C. difficile risk.","author":"Lowry"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/25\/Supplement_B\/B161\/50061177\/suad096.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/25\/Supplement_B\/B161\/50061177\/suad096.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T17:57:07Z","timestamp":1682099827000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/25\/Supplement_B\/B161\/7135801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":15,"journal-issue":{"issue":"Supplement_B","published-online":{"date-parts":[[2023,4,21]]},"published-print":{"date-parts":[[2023,4,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suad096","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2023,4,1]]}}}